Literature DB >> 6682673

Variation of receptor status in cancer of the breast.

R N Harland, D M Barnes, A Howell, G G Ribeiro, J Taylor, R A Sellwood.   

Abstract

One hundred and nineteen patients with breast cancer had 2 or more lesions removed for oestrogen (REc) or progesterone receptor (RPc) assay, either synchronously (on 38 occasions) or after an interval (on 91 occasions). In all but 7 both receptors were assayed for each lesion. The assays did not agree on the presence or absence of REc alone, RPc alone or the combination of both receptors in 11, 13 and 16% respectively of the synchronous samples, compared with 23, 30 and 43% of the asynchronous samples. The differences between the synchronous and asynchronous samples were significant for the combined receptors (P = 0.007) but not for REc (P = 0.176) or RPc alone (P = 0.077). Variation between asynchronous biopsies was greater when the earlier lesion contained RPc (18/37 disagreed) than when it did not (8/50) disagreed, P = 0.0023). This was not true for oestrogen receptor. In those remaining receptor positive there was only a weak correlation between the first and second values (Spearman rank correlation coefficient, rho = 0.39 for REc, P less than 0.02, and 0.45 for RPc, 0.05 less than P less than 0.1). Receptor levels and receptor status may change with time. Biopsy is most appropriate at the time when systemic treatment is proposed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6682673      PMCID: PMC2011332          DOI: 10.1038/bjc.1983.81

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  Estrogen receptor protein (ERP) in multiple tumor specimens from individual patients with breast cancer.

Authors:  P P Rosen; C J Menendez-Botet; J A Urban; A Fracchia; M K Schwartz
Journal:  Cancer       Date:  1977-05       Impact factor: 6.860

2.  Changes in multiple or sequential estrogen receptor determinations in breast cancer.

Authors:  J C Allegra; A Barlock; K K Huff; M E Lippman
Journal:  Cancer       Date:  1980-02-15       Impact factor: 6.860

3.  Oestradiol and progesterone receptors in multiple tumour specimens from patients with breast cancer.

Authors:  A Koenders; L Beex; A Smals; P Kloppenborg; T Benraad
Journal:  Neth J Med       Date:  1980       Impact factor: 1.422

4.  The value of progesterone receptor assays in the management of advanced breast cancer.

Authors:  G A Degenshein; N Bloom; E Tobin
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

5.  Endocrine ablation for metastatic breast cancer: a reappraisal of hormone receptors.

Authors:  H S Moseley; M E Peetz; E J Keenan; A E Awrich; W S Fletcher
Journal:  Am J Surg       Date:  1980-07       Impact factor: 2.565

6.  Analysis of estradiol and progesterone receptors in early and advanced breast tumors.

Authors:  R J King
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

7.  The variability of estrogen receptors in metastatic breast cancer.

Authors:  M J Brennan; W L Donegan; D E Appleby
Journal:  Am J Surg       Date:  1979-02       Impact factor: 2.565

8.  Studies on estrogen receptors and regression in human breast cancer.

Authors:  J K MacFarlane; D Fleiszer; A G Fazekas
Journal:  Cancer       Date:  1980-06-15       Impact factor: 6.860

9.  The role of progesterone receptors in the management of advanced breast cancer.

Authors:  N D Bloom; E H Tobin; B Schreibman; G A Degenshein
Journal:  Cancer       Date:  1980-06-15       Impact factor: 6.860

10.  Oestrogen-receptor status and sites of metastasis in breast cancer.

Authors:  F C Campbell; R W Blamey; C W Elston; R I Nicholson; K Griffiths; J L Haybittle
Journal:  Br J Cancer       Date:  1981-09       Impact factor: 7.640

View more
  6 in total

1.  Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay.

Authors:  G Saccani Jotti; S R Johnston; J Salter; S Detre; M Dowsett
Journal:  J Clin Pathol       Date:  1994-10       Impact factor: 3.411

2.  The relationship between estrogen receptors in primary and secondary breast carcinomas and in sequential primary breast carcinomas.

Authors:  R Hähnel; E Twaddle
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

3.  Nandrolone decanoate added to tamoxifen in the treatment of advanced breast cancer.

Authors:  E Heinonen; A Alanko; P Gröhn; P Rissanen
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

4.  Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer.

Authors:  S Detre; N King; J Salter; K MacLennan; J A McKinna; M Dowsett
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

Review 5.  Oestrogen receptor: a stable phenotype in breast cancer.

Authors:  J F Robertson
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

6.  Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women.

Authors:  R L Balleine; M J Earl; M L Greenberg; C L Clarke
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.